You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
A股異動丨政策助力,創新藥概念股拉昇,塞力醫療升停,昭衍新藥升超4%
A股市場創新藥概念股拉昇,其中,塞力醫療升停,舒泰神升近8%,諾思蘭德升近6%,昭衍新藥、翰宇藥業升超4%。消息面上,國家醫保局、國家衞生健康委印發《支持創新藥高質量發展的若干措施》提出,支持醫保數據用於創新藥研發。加強醫療、醫保、醫藥三方信息互通與協同,做好醫保數據資源管理,推動醫保領域公共數據資源利用。在確保數據安全、合法合規的基礎上,探索為創新藥研發提供必要的醫保數據服務。依託全國統一的醫保信息平台,做好疾病譜、臨牀用藥需求等數據歸集和分析,開發適配創新藥研發需求的數據產品,支持醫藥企業、科研院所、醫療機構等合理確定研發方向、佈局研發管線,提升創新效率。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.